Search

Your search keyword '"Vervueren, Laurent"' showing total 25 results
Start Over Author "Vervueren, Laurent"
25 results on '"Vervueren, Laurent"'

1. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

Author

Assenat, Eric, Delhom-Christol, Elisabeth, Fourcade, Marjolène, Guiu, Boris, Ilonca, Alina Diana, Lonjon, Julie, Pageaux, Georges-Philippe, Abdel-Rehim, Mohamed, Allaham, Wassim, Bouattour, Mohamed, Castera, Laurent, Dieudonné, Arnaud, Lebtahi, Rachida, Ronot, Maxime, Sibert, Annie, Vilgrain, Valérie, Chor, Hélène, Devictor, Julie, Barraud, Hélène, Bazin, Christophe, Bronowicki, Jean-Pierre, Imbert, Laetitia, Laurent, Valérie, Mathias, Elodie, Chagneau-Derrode, Carine, Gallais, Christelle, Perdrisot, Rémy, Silvain, Christine, Tasu, Jean Pierre, Borentain, Patrick, Farman, Bardia, Gerolami, René, Mundler, Olivier, Seitz, Jean-Francois, Vidal, Vincent, Aubé, Christophe, Bouchet, Francis, Bouvier, Antoine, Couturier, Olivier, Oberti, Frédéric, Vervueren, Laurent, Brenot-Rossi, Isabelle, Darreon, Julien, Raoul, Jean Luc, Sarran, Anthony, Chalaye, Julia, Costentin, Charlotte, Itti, Emmanuel, Kobeiter, Hicham, Luciani, Alain, Masset, Hélène, Adam, René, Lewin, Maïté, Samuel, Didier, Edeline, Julien, Garin, Etienne, Laffont, Sophie, Rolland, Yan, Archambeaud, Isabelle, Carlier, Thomas, Eugene, Thomas, Frampas, Eric, Cassinotto, Christophe, Guyot, Martine, Hiriart, Jean-Baptiste, Lapuyade, Bruno, Tendero, Karine, Vergniol, Julien, Bachellier, Philippe, Détour, Julien, Duclos, Bernard, Greget, Michel, Habersetzer, Francois, Imperiale, Alessio, Enderlin, Elise, Merle, Philippe, Rode, Agnès, Morvan, Julie, Nguyen-Khac, Eric, Talbot, Antoine, Yzet, Thierry, Baudin, Guillaume, Chevallier, Patrick, Mahamat, Abakar, Maurel, Fabien, Piche, Thierry, Razzouk, Micheline, Hillon, Patrick, Loffroy, Romaric, Toubeau, Michel, Vincent, Julie, Vrigneaud, Jean-Marc, Barabino, Gabriele, Bouarioua, Nadia, Cuilleron, Muriel, Ecochard, Marie, Prevot-Bitot, Nathalie, Rousset, Evelyne, Leroy, Vincent, Reboulet, Ghislaine, Roux, Julie, Sengel, Christian, Bourcier, Valérie, Ganne-Carrie, Nathalie, Seror, Olivier, Costo, Sylvie, Dao, Thông, Desmonts, Cédric, Pelage, Jean-Pierre, Defez, Didier, Dumortier, Jérôme, Giammarile, Francesco, Valette, Pierre-Jean, Bernardini, Michela, Ghazar, Nadia, Pellerin, Olivier, Taieb, Julien, Weinmann, Pierre, Heurgue-Berlot, Alexandra, Marcus, Claude, Sommacale, Daniele, Castilla-Lièvre, Maria-Angéla, Forbes, Aurélie, Maitre, Sophie, Marthey, Lysiane, Pereira, Helena, Burgio, Marco D., Grégory, Jules, and Chatellier, Gilles

Published
2021
Full Text
View/download PDF

2. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Author

Assenat, Eric, Delhom-Christol, Elisabeth, Guiu, Boris, Ilonca, Alina D., Lonjon, Julie, Pageaux, Georges-Philippe, Abdel-Rehim, Mohamed, Al-laham, Wassim, Bouattour, Mohamed, Castera, Laurent, Dieudonné, Arnaud, Lebtahi, Rachida, Ronot, Maxime, Sibert, Annie, Vilgrain, Valérie, Barraud, Hélène, Bazin, Christophe, Bronowicki, Jean-Pierre, Laurent, Valérie, Mathias, Elodie, Chagneau-Derrode, Carine, Perdrisot, Rémy, Silvain, Christine, Tasu, Jean-Pierre, RenéGerolami, Patrick Borentain, Mundler, Olivier, Seitz, Jean-Francois, Vidal, Vincent, Aubé, Christophe, Bouvier, Antoine, Couturier, Olivier, Oberti, Frédéric, Vervueren, Laurent, Brenot-Rossi, Isabelle, Raoul, Jean-Luc, Sar-ran, Anthony, Chalaye, Julia, Costentin, Charlotte, Itti, Emmanuel, Kobeiter, Hicham, Luciani, Alain, Adam, René, Lewin, Maïté, Samuel, Didier, Edeline, Julien, Garin, Etienne, Rolland, Yan, Archambeaud, Isabelle, Eugene, Thomas, Frampas, Eric, Cassinotto, Christophe, Guyot, Martine, Hiriart, Jean-Baptiste, Lapuyade, Bruno, Vergniol, Julien, Bachellier, Philippe, Detour, Julien, Duclos, Bernard, Greget, Michel, Habersetzer, Francois, Imperiale, Alessio, Merle, Philippe, Rode, Agnès, Morvan, Julie, Nguyen-Khac, Eric, Yzet, Thierry, Baudin, Guillaume, Chevallier, Patrick, Mahamat, Abakar, Piche, Thierry, Razzouk, Micheline, Hillon, Patrick, Loffroy, Romaric, Toubeau, Michel, Vincent, Julie, Barabino, Gabriele, Bouarioua, Nadia, Cuilleron, Muriel, Ecochard, Marie, Prevot-Bitot, Nathalie, Leroy, Vincent, Roux, Julie, Sengel, Christian, Bourcier, Valérie, Carrie, Nathalie Ganne, Seror, Olivier, Costo, Sylvie, Dao, Thông, Pelage, Jean-Pierre, Dumortier, Jérôme, Giammarile, Francesco, Valette, Pierre-Jean, Ghazzar, Nadia, Pellerin, Olivier, Taieb, Julien, Weinmann, Pierre, Berlot, Alexandra Heurgue, Marcus, Claude, Sommacale, Daniele, Castilla-Lièvre, Maria-Angéla, Maitre, Sophie, Marthey, Lysiane, Zarca, Kevin, Mimouni, Maroua, Pereira, Helena, Chatellier, Gilles, and Durand-Zaleski, Isabelle

Published
2021
Full Text
View/download PDF

3. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Author

Assenat, Eric, Delhom - Christol, Elisabeth, Guiu, Boris, Ilonca, Alina D, Lonjon, Julie, Pageaux, Georges-Philippe, Abdel-Rehim, Mohamed, Allaham, Wassim, Bouattour, Mohamed, Castera, Laurent, Dieudonné, Arnaud, Lebtahi, Rachida, Ronot, Maxime, Sibert, Annie, Vilgrain, Valérie, Barraud, Hélène, Bazin, Christophe, Bronowicki, Jean-Pierre, Laurent, Valérie, Mathias, Elodie, Chagneau-Derrode, Carine, Perdrisot, Rémy, Silvain, Christine, Tasu, Jean-Pierre, Borentain, Patrick, Gerolami, René, Mundler, Olivier, Seitz, Jean-Francois, Vidal, Vincent, Aubé, Christophe, Bouvier, Antoine, Couturier, Olivier, Oberti, Frédéric, Vervueren, Laurent, Brenot-Rossi, Isabelle, Raoul, Jean-Luc, Sarran, Anthony, Chalaye, Julia, Costentin, Charlotte, Itti, Emmanuel, Kobeiter, Hicham, Luciani, Alain, Adam, René, Lewin, Maïté, Samuel, Didier, Edeline, Julien, Garin, Etienne, Rolland, Yan, Archambeaud, Isabelle, Eugene, Thomas, Frampas, Eric, Cassinotto, Christophe, Guyot, Martine, Hiriart, Jean-Baptiste, Lapuyade, Bruno, Vergniol, Julien, Bachellier, Philippe, Detour, Julien, Duclos, Bernard, Greget, Michel, Habersetzer, Francois, Imperiale, Alessio, Merle, Philippe, Rode, Agnès, Morvan, Julie, Nguyen-Khac, Eric, Yzet, Thierry, Baudin, Guillaume, Chevallier, Patrick, Mahamat, Abakar, Piche, Thierry, Razzouk, Micheline, Hillon, Patrick, Loffroy, Romaric, Toubeau, Michel, Vincent, Julie, Barabino, Gabriele, Bouarioua, Nadia, Cuilleron, Muriel, Ecochard, Marie, Prevot-Bitot, Nathalie, Leroy, Vincent, Roux, Julie, Sengel, Christian, Bourcier, Valérie, Ganne-Carrie, Nathalie, Seror, Olivier, Costo, Sylvie, Dao, Thông, Pelage, Jean-Pierre, Dumortier, Jérôme, Giammarile, Francesco, Valette, Pierre-Jean, Ghazzar, Nadia, Pellerin, Olivier, Taieb, Julien, Weinmann, Pierre, Heurgue-Berlot, Alexandra, Marcus, Claude, Sommacale, Daniele, Castilla-Lièvre, Maria-Angéla, Maitre, Sophie, Marthey, Lysiane, Pereira, Helena, Ilonca, Alina Diana, Dinut, Aurelia, and Chatellier, Gilles

Published
2017
Full Text
View/download PDF

4. Study protocol of the HYPER-LIV01 trial: a multicenter phase II, prospective and randomized study comparing simultaneous portal and hepatic vein embolization to portal vein embolization for hypertrophy of the future liver remnant before major hepatectomy for colo-rectal liver metastases

Author

Deshayes, Emmanuel, Piron, Lauranne, Bouvier, Antoine, Lapuyade, Bruno, Lermite, Emilie, Vervueren, Laurent, Laurent, Christophe, Pinaquy, Jean-Baptiste, Chevallier, Patrick, Dohan, Anthony, Rode, Agnès, Sengel, Christian, Guillot, Chloé, Quenet, François, and Guiu, Boris

Published
2020
Full Text
View/download PDF

5. Improved identification of good candidates for the treatment of intermediate/advanced hepatocellular carcinoma by Yttrium-90 transarterial radioembolization

Author

Vitellius, Carole, primary, Poulard, Severine, additional, Fontana, Julien, additional, Oreistein, Ines, additional, Fosse, Pacome, additional, Paisant, Anita, additional, Vervueren, Laurent, additional, Oberti, Frédéric, additional, Aubé, Christophe, additional, Laceuille, Franck, additional, and Boursier, Jerome, additional

Published
2023
Full Text
View/download PDF

8. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

Author

Pereira, Helena, primary, Bouattour, Mohamed, additional, Burgio, Marco D., additional, Assenat, Eric, additional, Grégory, Jules, additional, Bronowicki, Jean-Pierre, additional, Chatellier, Gilles, additional, Vilgrain, Valérie, additional, Delhom-Christol, Elisabeth, additional, Fourcade, Marjolène, additional, Guiu, Boris, additional, Ilonca, Alina Diana, additional, Lonjon, Julie, additional, Pageaux, Georges-Philippe, additional, Abdel-Rehim, Mohamed, additional, Allaham, Wassim, additional, Castera, Laurent, additional, Dieudonné, Arnaud, additional, Lebtahi, Rachida, additional, Ronot, Maxime, additional, Sibert, Annie, additional, Chor, Hélène, additional, Devictor, Julie, additional, Barraud, Hélène, additional, Bazin, Christophe, additional, Imbert, Laetitia, additional, Laurent, Valérie, additional, Mathias, Elodie, additional, Chagneau-Derrode, Carine, additional, Gallais, Christelle, additional, Perdrisot, Rémy, additional, Silvain, Christine, additional, Tasu, Jean Pierre, additional, Borentain, Patrick, additional, Farman, Bardia, additional, Gerolami, René, additional, Mundler, Olivier, additional, Seitz, Jean-Francois, additional, Vidal, Vincent, additional, Aubé, Christophe, additional, Bouchet, Francis, additional, Bouvier, Antoine, additional, Couturier, Olivier, additional, Oberti, Frédéric, additional, Vervueren, Laurent, additional, Brenot-Rossi, Isabelle, additional, Darreon, Julien, additional, Raoul, Jean Luc, additional, Sarran, Anthony, additional, Chalaye, Julia, additional, Costentin, Charlotte, additional, Itti, Emmanuel, additional, Kobeiter, Hicham, additional, Luciani, Alain, additional, Masset, Hélène, additional, Adam, René, additional, Lewin, Maïté, additional, Samuel, Didier, additional, Edeline, Julien, additional, Garin, Etienne, additional, Laffont, Sophie, additional, Rolland, Yan, additional, Archambeaud, Isabelle, additional, Carlier, Thomas, additional, Eugene, Thomas, additional, Frampas, Eric, additional, Cassinotto, Christophe, additional, Guyot, Martine, additional, Hiriart, Jean-Baptiste, additional, Lapuyade, Bruno, additional, Tendero, Karine, additional, Vergniol, Julien, additional, Bachellier, Philippe, additional, Détour, Julien, additional, Duclos, Bernard, additional, Greget, Michel, additional, Habersetzer, Francois, additional, Imperiale, Alessio, additional, Enderlin, Elise, additional, Merle, Philippe, additional, Rode, Agnès, additional, Morvan, Julie, additional, Nguyen-Khac, Eric, additional, Talbot, Antoine, additional, Yzet, Thierry, additional, Baudin, Guillaume, additional, Chevallier, Patrick, additional, Mahamat, Abakar, additional, Maurel, Fabien, additional, Piche, Thierry, additional, Razzouk, Micheline, additional, Hillon, Patrick, additional, Loffroy, Romaric, additional, Toubeau, Michel, additional, Vincent, Julie, additional, Vrigneaud, Jean-Marc, additional, Barabino, Gabriele, additional, Bouarioua, Nadia, additional, Cuilleron, Muriel, additional, Ecochard, Marie, additional, Prevot-Bitot, Nathalie, additional, Rousset, Evelyne, additional, Leroy, Vincent, additional, Reboulet, Ghislaine, additional, Roux, Julie, additional, Sengel, Christian, additional, Bourcier, Valérie, additional, Ganne-Carrie, Nathalie, additional, Seror, Olivier, additional, Costo, Sylvie, additional, Dao, Thông, additional, Desmonts, Cédric, additional, Pelage, Jean-Pierre, additional, Defez, Didier, additional, Dumortier, Jérôme, additional, Giammarile, Francesco, additional, Valette, Pierre-Jean, additional, Bernardini, Michela, additional, Ghazar, Nadia, additional, Pellerin, Olivier, additional, Taieb, Julien, additional, Weinmann, Pierre, additional, Heurgue-Berlot, Alexandra, additional, Marcus, Claude, additional, Sommacale, Daniele, additional, Castilla-Lièvre, Maria-Angéla, additional, Forbes, Aurélie, additional, Maitre, Sophie, additional, and Marthey, Lysiane, additional

Published
2021
Full Text
View/download PDF

9. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

Author

Zarca, Kevin, primary, Mimouni, Maroua, additional, Pereira, Helena, additional, Chatellier, Gilles, additional, Vilgrain, Valérie, additional, Durand-Zaleski, Isabelle, additional, Assenat, Eric, additional, Delhom-Christol, Elisabeth, additional, Guiu, Boris, additional, Ilonca, Alina D., additional, Lonjon, Julie, additional, Pageaux, Georges-Philippe, additional, Abdel-Rehim, Mohamed, additional, Al-laham, Wassim, additional, Bouattour, Mohamed, additional, Castera, Laurent, additional, Dieudonné, Arnaud, additional, Lebtahi, Rachida, additional, Ronot, Maxime, additional, Sibert, Annie, additional, Barraud, Hélène, additional, Bazin, Christophe, additional, Bronowicki, Jean-Pierre, additional, Laurent, Valérie, additional, Mathias, Elodie, additional, Chagneau-Derrode, Carine, additional, Perdrisot, Rémy, additional, Silvain, Christine, additional, Tasu, Jean-Pierre, additional, RenéGerolami, Patrick Borentain, additional, Mundler, Olivier, additional, Seitz, Jean-Francois, additional, Vidal, Vincent, additional, Aubé, Christophe, additional, Bouvier, Antoine, additional, Couturier, Olivier, additional, Oberti, Frédéric, additional, Vervueren, Laurent, additional, Brenot-Rossi, Isabelle, additional, Raoul, Jean-Luc, additional, Sar-ran, Anthony, additional, Chalaye, Julia, additional, Costentin, Charlotte, additional, Itti, Emmanuel, additional, Kobeiter, Hicham, additional, Luciani, Alain, additional, Adam, René, additional, Lewin, Maïté, additional, Samuel, Didier, additional, Edeline, Julien, additional, Garin, Etienne, additional, Rolland, Yan, additional, Archambeaud, Isabelle, additional, Eugene, Thomas, additional, Frampas, Eric, additional, Cassinotto, Christophe, additional, Guyot, Martine, additional, Hiriart, Jean-Baptiste, additional, Lapuyade, Bruno, additional, Vergniol, Julien, additional, Bachellier, Philippe, additional, Detour, Julien, additional, Duclos, Bernard, additional, Greget, Michel, additional, Habersetzer, Francois, additional, Imperiale, Alessio, additional, Merle, Philippe, additional, Rode, Agnès, additional, Morvan, Julie, additional, Nguyen-Khac, Eric, additional, Yzet, Thierry, additional, Baudin, Guillaume, additional, Chevallier, Patrick, additional, Mahamat, Abakar, additional, Piche, Thierry, additional, Razzouk, Micheline, additional, Hillon, Patrick, additional, Loffroy, Romaric, additional, Toubeau, Michel, additional, Vincent, Julie, additional, Barabino, Gabriele, additional, Bouarioua, Nadia, additional, Cuilleron, Muriel, additional, Ecochard, Marie, additional, Prevot-Bitot, Nathalie, additional, Leroy, Vincent, additional, Roux, Julie, additional, Sengel, Christian, additional, Bourcier, Valérie, additional, Carrie, Nathalie Ganne-, additional, Seror, Olivier, additional, Costo, Sylvie, additional, Dao, Thông, additional, Pelage, Jean-Pierre, additional, Dumortier, Jérôme, additional, Giammarile, Francesco, additional, Valette, Pierre-Jean, additional, Ghazzar, Nadia, additional, Pellerin, Olivier, additional, Taieb, Julien, additional, Weinmann, Pierre, additional, Berlot, Alexandra Heurgue-, additional, Marcus, Claude, additional, Sommacale, Daniele, additional, Castilla-Lièvre, Maria-Angéla, additional, Maitre, Sophie, additional, and Marthey, Lysiane, additional

Published
2021
Full Text
View/download PDF

13. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Author

Vilgrain, Valérie, primary, Pereira, Helena, additional, Assenat, Eric, additional, Guiu, Boris, additional, Ilonca, Alina Diana, additional, Pageaux, Georges-Philippe, additional, Sibert, Annie, additional, Bouattour, Mohamed, additional, Lebtahi, Rachida, additional, Allaham, Wassim, additional, Barraud, Hélène, additional, Laurent, Valérie, additional, Mathias, Elodie, additional, Bronowicki, Jean-Pierre, additional, Tasu, Jean-Pierre, additional, Perdrisot, Rémy, additional, Silvain, Christine, additional, Gerolami, René, additional, Mundler, Olivier, additional, Seitz, Jean-Francois, additional, Vidal, Vincent, additional, Aubé, Christophe, additional, Oberti, Frédéric, additional, Couturier, Olivier, additional, Brenot-Rossi, Isabelle, additional, Raoul, Jean-Luc, additional, Sarran, Anthony, additional, Costentin, Charlotte, additional, Itti, Emmanuel, additional, Luciani, Alain, additional, Adam, René, additional, Lewin, Maïté, additional, Samuel, Didier, additional, Ronot, Maxime, additional, Dinut, Aurelia, additional, Castera, Laurent, additional, Chatellier, Gilles, additional, Delhom - Christol, Elisabeth, additional, Ilonca, Alina D, additional, Lonjon, Julie, additional, Abdel-Rehim, Mohamed, additional, Dieudonné, Arnaud, additional, Vilgrain, Valérie, additional, Bazin, Christophe, additional, Chagneau-Derrode, Carine, additional, Borentain, Patrick, additional, Bouvier, Antoine, additional, Vervueren, Laurent, additional, Chalaye, Julia, additional, Kobeiter, Hicham, additional, Edeline, Julien, additional, Garin, Etienne, additional, Rolland, Yan, additional, Archambeaud, Isabelle, additional, Eugene, Thomas, additional, Frampas, Eric, additional, Cassinotto, Christophe, additional, Guyot, Martine, additional, Hiriart, Jean-Baptiste, additional, Lapuyade, Bruno, additional, Vergniol, Julien, additional, Bachellier, Philippe, additional, Detour, Julien, additional, Duclos, Bernard, additional, Greget, Michel, additional, Habersetzer, Francois, additional, Imperiale, Alessio, additional, Merle, Philippe, additional, Rode, Agnès, additional, Morvan, Julie, additional, Nguyen-Khac, Eric, additional, Yzet, Thierry, additional, Baudin, Guillaume, additional, Chevallier, Patrick, additional, Mahamat, Abakar, additional, Piche, Thierry, additional, Razzouk, Micheline, additional, Hillon, Patrick, additional, Loffroy, Romaric, additional, Toubeau, Michel, additional, Vincent, Julie, additional, Barabino, Gabriele, additional, Bouarioua, Nadia, additional, Cuilleron, Muriel, additional, Ecochard, Marie, additional, Prevot-Bitot, Nathalie, additional, Leroy, Vincent, additional, Roux, Julie, additional, Sengel, Christian, additional, Bourcier, Valérie, additional, Ganne-Carrie, Nathalie, additional, Seror, Olivier, additional, Costo, Sylvie, additional, Dao, Thông, additional, Pelage, Jean-Pierre, additional, Dumortier, Jérôme, additional, Giammarile, Francesco, additional, Valette, Pierre-Jean, additional, Ghazzar, Nadia, additional, Pellerin, Olivier, additional, Taieb, Julien, additional, Weinmann, Pierre, additional, Heurgue-Berlot, Alexandra, additional, Marcus, Claude, additional, Sommacale, Daniele, additional, Castilla-Lièvre, Maria-Angéla, additional, Maitre, Sophie, additional, and Marthey, Lysiane, additional

Published
2017
Full Text
View/download PDF

14. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18F-Misonidazole PET/CT in Patients with Non–Small Cell Lung Carcinoma (RTEP5 Study)

Author

Vera, Pierre, primary, Thureau, Sébastien, additional, Chaumet-Riffaud, Philippe, additional, Modzelewski, Romain, additional, Bohn, Pierre, additional, Vermandel, Maximilien, additional, Hapdey, Sébastien, additional, Pallardy, Amandine, additional, Mahé, Marc-André, additional, Lacombe, Marie, additional, Boisselier, Pierre, additional, Guillemard, Sophie, additional, Olivier, Pierre, additional, Beckendorf, Veronique, additional, Salem, Naji, additional, Charrier, Nathalie, additional, Chajon, Enrique, additional, Devillers, Anne, additional, Aide, Nicolas, additional, Danhier, Serge, additional, Denis, Fabrice, additional, Muratet, Jean-Pierre, additional, Martin, Etienne, additional, Riedinger, Alina Berriolo, additional, Kolesnikov-Gauthier, Helène, additional, Dansin, Eric, additional, Massabeau, Carole, additional, Courbon, Fredéric, additional, Farcy Jacquet, Marie-Pierre, additional, Kotzki, Pierre-Olivier, additional, Houzard, Claire, additional, Mornex, Francoise, additional, Vervueren, Laurent, additional, Paumier, Amaury, additional, Fernandez, Philippe, additional, Salaun, Mathieu, additional, and Dubray, Bernard, additional

Published
2017
Full Text
View/download PDF

16. [¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients

Author

Hachemi, Mammar, Couturier, Olivier-François, Vervueren, Laurent, Fosse, Pacôme, Lacœuille, Franck, Urban, Thierry, Hureaux, José, Univ Angers, Okina, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Micro et Nanomédecines Biomimétiques (MINT), and Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL)

Subjects
Adult, Male, Survival rate, Lung Neoplasms, Time Factors, [SDV]Life Sciences [q-bio], Carcinoma, lcsh:R, lcsh:Medicine, Middle Aged, Disease-Free Survival, [SDV] Life Sciences [q-bio], Fluorodeoxyglucose F18, Positron-Emission Tomography, Quinazolines, Humans, Female, lcsh:Q, Radiopharmaceuticals, Non-Small-Cell Lung, lcsh:Science, Protein Kinase Inhibitors, Aged
Abstract

International audience; PURPOSE: The aim of this prospective study was to evaluate whether [¹⁸F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in patients with inoperable (stage IIIA to IV) non-small cell lung cancer patients.PATIENTS AND METHODS: Three [¹⁸F]FDG-PET/CT scans were acquired in 12 patients before (5±4 days) and after 9±3 days (early PET) and 60±6 days (late PET) of erlotinib therapy. Conventional evaluation, including at least chest CT (baseline versus after 8 weeks of treatment), was performed according to RECIST 1.1 criteria. Change in [¹⁸F]FDG uptake was compared with conventional response, progression-free survival (PFS), and overall survival (OS).RESULTS: By using ROC analysis, the Area Under the Curve for prediction of metabolic non-progressive disease (mNP) by early PET was 0.86 (95% CI, 0.62 to 1.1; P = 0.04) at a cut-off of 21.6% reduction in maximum Standardized Uptake Value (SUVmax). This correctly classified 11/12 patients (7 with true progressive disease; 4 with true non-progressive disease; 1 with false progressive disease). Non-progressive disease after 8 weeks of treatment according to RECIST 1.1 criteria was significantly more frequent in patients classified mNP (P = 0.01, Fisher's exact test). mNP patients showed prolonged PFS (HR = 0.27; 95% CI, 0.04 to 0.59; P

Published
2014
Full Text
View/download PDF

17. Interobserver agreement of qualitative analysis and tumor delineation of FMISO and FLT PET-images in lung cancer

Author

Thureau, Sébastien, Chaumet Riffaud, Philippe, Modzelewski, Romain, Fernandez, Philippe, Tessonnier, Laurent, Vervueren, Laurent, Cachin, Florent, Berriolo-Riedinger, Alina, Olivier, Pierre, Kolesnikov-Gauthier, Hélène, Blagosklonov, Oleg, Bridji, Boumediene, Devillers, Anne, Collombier, Laurent, Courbon, Frederic, Gremillet, Eric, Houzard, Claire, Caignon, Jean-Marc, Roux, Julie, Aide, Nicolas, Brenot-Rossi, Isabelle, Doyeux, Kaya, Dubray, Bernard, Vera, Pierre, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Université Le Havre Normandie (ULH), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Université Le Havre Normandie (ULH), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA), Service de Biophysique et de Médecine Nucléaire, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Médecine nucléaire, biophysique, isotopes [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Département de médecine nucléaire [Rennes], CRLCC Eugène Marquis (CRLCC), Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Claudius Regaud, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Dept. of Nucl. Med., Jean Minjoz Univ. Hosp., Besancon, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), CRLCC Institut Claudius Regaud, Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), and Breton, Céline

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2013

18. Comparison between the diagnostic value of 18F-FDG PET-CT and 99mTc-HMPAO-labeled leukocyte scintigraphy (with SPECT-CT) in vascular prothesis infection

Author

Agius, C., Rakotonirina, Hervé, Lacœuille, Franck, Bouchet, Francis, Vervueren, Laurent, Le Jeune, Jean-Jacques, Couturier, Olivier-François, Univ Angers, Okina, Micro et Nanomédecines Biomimétiques (MINT), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL), Centre Hospitalier Universitaire d'Angers (CHU Angers), and PRES Université Nantes Angers Le Mans (UNAM)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio]
Abstract

Contribution issue du 24e Congrès annuel de l'Association européenne de médecine nucléaire, organisé les 15, 16, 17, 18 et 19 octobre 2011 à Birmingham au Royaume-Uni.; International audience

Published
2011

19. 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) can identify chronic lymphocytic leukaemia (CLL) stage A et stage B patients

Author

Berthelot, Cécile, Truchan-Graczyk, Malgorzata, Geneviève, Franck, Poirier, Anne-Lise, Artur-Guillemette, P., Vervueren, Laurent, Ifrah, Norbert, Le Jeune, Jean-Jacques, Couturier, Olivier-François, Laboratoire d'hématologie, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), PRES Université Nantes Angers Le Mans (UNAM), Apoptosis and Tumor Progression (CRCINA-ÉQUIPE 9), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Micro et Nanomédecines Biomimétiques (MINT), and Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Bretagne Loire (UBL)

Subjects
Adult, Male, Chronic lymphocytic leukaemia, positron emission tomography, area under the curve, FDG, [SDV]Life Sciences [q-bio], Sensitivity and Specificity, Student t test, image analysis, controlled study, Aged, clinical article, receiver operating characteristic, cancer staging, article, Fluorodeoxyglucose, mediastinum, axillary lymph node, fluorodeoxyglucose f 18, PET, diaphragm, Female, diagnostic value, chronic lymphatic leukemia, Human
Abstract

International audience; Purpose: There is no data in the literature concerning the utility of 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in chronic lymphocytic leukaemia (CLL), except for the diagnosis of Richter's transformations. The purpose of this study was to assess the potential role of FDG-PET in CLL stages A and B. Materials and methods: Thirty-five patients (61 ± 9 years; 11 women, 24 men; 8B and 27A) have benefited of a FDG-PET scan at baseline, for example, before an eventual treatment. FDG-PET scans were analyzed visually and the maximum values of the Standardised Uptake Value (SUVmax) were measured in the main lymph nodes areas. The ability of FDG-PET to differentiate stages A and B patients was evaluated by Student's tests and Receiver Operating Characteristics (ROC) analysis. Results: All patients with a normal FDG-PET (n = 18) were stages A. The remaining 17 patients (9A and 8B) showed hypermetabolisms in nodal areas above (n = 17) and below (n = 9) the diaphragm, and no visceral involvement. The lymph nodes hypermetabolisms were always bilateral, and of low intensity (≤ mediastinum; 9A), or of higher intensity (≥ liver, 8B). The SUVmax of stage B (n = 8) were significantly higher than those of the 27 stages A, in all lymph nodes areas except in mediastinum. The highest intensity of FDG uptake was observed in axillary area in stages B patients (SUVmax = 2.74 ± 1.03). An axillary SUVmax of 1.33 is the most suitable value for the discrimination between stages A and B patients (ROC; AUC = 0.968; sensitivity 1.00; specificity 0.91). Conclusion: Lymph nodes hypermetabolisms are constant in the B stage, and more intense than in stage A. These anomalies are always bilateral, unlike what is observed in Richter's transformation. The intensity of axillary lymph nodes FDG uptake can distinguish CLL stages A and B.

Published
2009
Full Text
View/download PDF

21. Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3′-Deoxy-3′-18F-Fluorothymidine PET Images in Lung Cancer

Author

Thureau, Sébastien, primary, Chaumet-Riffaud, Philippe, additional, Modzelewski, Romain, additional, Fernandez, Philippe, additional, Tessonnier, Laurent, additional, Vervueren, Laurent, additional, Cachin, Florent, additional, Berriolo-Riedinger, Alina, additional, Olivier, Pierre, additional, Kolesnikov-Gauthier, Hélène, additional, Blagosklonov, Oleg, additional, Bridji, Boumediene, additional, Devillers, Anne, additional, Collombier, Laurent, additional, Courbon, Fréderic, additional, Gremillet, Eric, additional, Houzard, Claire, additional, Caignon, Jean Marc, additional, Roux, Julie, additional, Aide, Nicolas, additional, Brenot-Rossi, Isabelle, additional, Doyeux, Kaya, additional, Dubray, Bernard, additional, and Vera, Pierre, additional

Published
2013
Full Text
View/download PDF

22. [18F]FDG Positron Emission Tomography within Two Weeks of Starting Erlotinib Therapy Can Predict Response in Non-Small Cell Lung Cancer Patients.

Author

Hachemi, Mammar, Couturier, Olivier, Vervueren, Laurent, Fosse, Pacôme, Lacœuille, Franck, Urban, Thierry, and Hureaux, José

Subjects
LUNG cancer treatment, POSITRON emission tomography, ERLOTINIB, LUNG cancer patients, LONGITUDINAL method, CANCER tomography, CANCER invasiveness, THERAPEUTICS
Abstract

Purpose: The aim of this prospective study was to evaluate whether [18F]FDG-PET/CT, performed within two weeks of starting erlotinib therapy can predict tumor response defined by RECIST 1.1 criteria after 8 weeks of treatment in patients with inoperable (stage IIIA to IV) non-small cell lung cancer patients. Patients and Methods: Three [18F]FDG-PET/CT scans were acquired in 12 patients before (5±4 days) and after 9±3 days (early PET) and 60±6 days (late PET) of erlotinib therapy. Conventional evaluation, including at least chest CT (baseline versus after 8 weeks of treatment), was performed according to RECIST 1.1 criteria. Change in [18F]FDG uptake was compared with conventional response, progression-free survival (PFS), and overall survival (OS). Results: By using ROC analysis, the Area Under the Curve for prediction of metabolic non-progressive disease (mNP) by early PET was 0.86 (95% CI, 0.62 to 1.1; P = 0.04) at a cut-off of 21.6% reduction in maximum Standardized Uptake Value (SUVmax). This correctly classified 11/12 patients (7 with true progressive disease; 4 with true non-progressive disease; 1 with false progressive disease). Non-progressive disease after 8 weeks of treatment according to RECIST 1.1 criteria was significantly more frequent in patients classified mNP (P = 0.01, Fisher's exact test). mNP patients showed prolonged PFS (HR = 0.27; 95% CI, 0.04 to 0.59; P<0.01) and OS (HR = 0.34; 95% CI, 0.06 to 0.84; P = 0.03). Late PET analysis provided concordant results. Conclusion: Morphologic response, PFS and OS survival in non-small cell lung cancer patients can be predicted by [18F]FDG-PET/CT scan within 2 weeks after starting erlotinib therapy. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

23. Interobserver Agreement of Qualitative Analysis and Tumor Delineation of 18F-Fluoromisonidazole and 3'-Deoxy-3'-18F-Fluorothymidine PET Images in Lung Cancer.

Author

Thureau, Sébastien, Chaumet-Riffaud, Philippe, Modzelewski, Romain, Fernandez, Philippe, Tessonnier, Laurent, Vervueren, Laurent, Cachin, Florent, Berriolo-Riedinger, Alina, Olivier, Pierre, Kolesnikov-Gauthier, Hélène, Blagosklonov, Oleg, Bridji, Boumediene, Devillers, Anne, Collombier, Laurent, Courbon, Fréderic, Gremillet, Eric, Houzard, Claire, Caignon, Jean Marc, Roux, Julie, and Aide, Nicolas

Published
2013
Full Text
View/download PDF

24. Long-term prognostic significance of right bundle-branch morphology ventricular ectopy induced during stress test in patients with intermediate to high probability of coronary artery disease.

Author

Bière L, Mezdad TH, Dupuis JM, Vervueren L, Rakotonirina H, Prunier F, and Furber A

Subjects
Aged, Bundle-Branch Block diagnosis, Bundle-Branch Block mortality, Bundle-Branch Block physiopathology, Coronary Artery Disease mortality, Coronary Artery Disease physiopathology, Electrocardiography, Ambulatory, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Risk Factors, Stroke Volume, Time Factors, Ventricular Function, Left, Ventricular Premature Complexes diagnosis, Ventricular Premature Complexes mortality, Ventricular Premature Complexes physiopathology, Bundle-Branch Block etiology, Coronary Artery Disease diagnostic imaging, Exercise Test adverse effects, Tomography, Emission-Computed, Single-Photon, Ventricular Premature Complexes etiology
Abstract

Aims: Stress-induced right bundle-branch block morphology ventricular ectopy (SI-RBVE) may be caused by left ventricular myocardial anomalies. While frequent ventricular ectopy (FVE) has been linked to poor outcomes, the prognostic value of SI-RBVE has not been established. The study aims to determine whether SI-RBVE is associated with increased mortality., Methods and Results: Three hundred forty-three patients with an intermediate to high probability of coronary artery disease were prospectively included. Patients were referred for a single-photon emission computed tomography and underwent a stress test according to standard protocols. Stress-induced right bundle-branch block morphology ventricular ectopy (VE) was defined as one or more induced premature beats with positive predominance in V1. Frequent VE was defined as the presence of seven or more ventricular premature beats per minute or any organized ventricular arrhythmia. During a mean follow-up of 4.5 ± 1.3 years, 59 deaths occurred. The death rate was higher in the SI-RBVE group (23.4% vs. 14.0%, P = 0.021). Age [odds ratio (OR) = 1.09 (95% CI: 1.06-1.13), P < 0.001] and peripheral artery disease [OR = 2.47 (95% CI: 1.35-4.50) P = 0.003] were independent factors of mortality, but single-photon emission computed tomography findings were not. There was an interaction between SI-RBVE and left ventricular ejection fraction (LVEF). In patients with LVEF > 50%, SI-RBVE was an incremental risk factor for mortality [OR = 2.83 (95% CI: 1.40-5.74), P = 0.004]. Stress-induced right bundle-branch block morphology VE patients also presented higher rates of known coronary artery disease, ischaemia, scar, and ST-segment changes. Frequent VE was not related to mortality., Conclusion: Stress-induced right bundle-branch block morphology VE is associated with an increased mortality in patients with preserved LVEF., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.)

Published
2018
Full Text
View/download PDF

25. Phase II Study of a Radiotherapy Total Dose Increase in Hypoxic Lesions Identified by 18 F-Misonidazole PET/CT in Patients with Non-Small Cell Lung Carcinoma (RTEP5 Study).

Author

Vera P, Thureau S, Chaumet-Riffaud P, Modzelewski R, Bohn P, Vermandel M, Hapdey S, Pallardy A, Mahé MA, Lacombe M, Boisselier P, Guillemard S, Olivier P, Beckendorf V, Salem N, Charrier N, Chajon E, Devillers A, Aide N, Danhier S, Denis F, Muratet JP, Martin E, Riedinger AB, Kolesnikov-Gauthier H, Dansin E, Massabeau C, Courbon F, Farcy Jacquet MP, Kotzki PO, Houzard C, Mornex F, Vervueren L, Paumier A, Fernandez P, Salaun M, and Dubray B

Subjects
Carcinoma, Non-Small-Cell Lung diagnostic imaging, Female, France, Humans, Lung Neoplasms diagnostic imaging, Male, Middle Aged, Misonidazole pharmacokinetics, Observer Variation, Radiopharmaceuticals pharmacokinetics, Reproducibility of Results, Sensitivity and Specificity, Survival Rate, Treatment Outcome, Tumor Hypoxia radiation effects, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Non-Small-Cell Lung radiotherapy, Dose Fractionation, Radiation, Lung Neoplasms metabolism, Lung Neoplasms radiotherapy, Misonidazole analogs & derivatives
Abstract

See an invited perspective on this article on page 1043.This multicenter phase II study investigated a selective radiotherapy dose increase to tumor areas with significant 18 F-misonidazole ( 18 F-FMISO) uptake in patients with non-small cell lung carcinoma (NSCLC). Methods: Eligible patients had locally advanced NSCLC and no contraindication to concomitant chemoradiotherapy. The 18 F-FMISO uptake on PET/CT was assessed by trained experts. If there was no uptake, 66 Gy were delivered. In 18 F-FMISO-positive patients, the contours of the hypoxic area were transferred to the radiation oncologist. It was necessary for the radiotherapy dose to be as high as possible while fulfilling dose-limiting constraints for the spinal cord and lungs. The primary endpoint was tumor response (complete response plus partial response) at 3 mo. The secondary endpoints were toxicity, disease-free survival (DFS), and overall survival at 1 y. The target sample size was set to demonstrate a response rate of 40% or more (bilateral α = 0.05, power 1-β = 0.95). Results: Seventy-nine patients were preincluded, 54 were included, and 34 were 18 F-FMISO-positive, 24 of whom received escalated doses of up to 86 Gy. The response rate at 3 mo was 31 of 54 (57%; 95% confidence interval [CI], 43%-71%) using RECIST 1.1 (17/34 responders in the 18 F-FMISO-positive group). DFS and overall survival at 1 y were 0.86 (95% CI, 0.77-0.96) and 0.63 (95% CI, 0.49-0.74), respectively. DFS was longer in the 18 F-FMISO-negative patients ( P = 0.004). The radiotherapy dose was not associated with DFS when adjusting for the 18 F-FMISO status. One toxic death (66 Gy) and 1 case of grade 4 pneumonitis (>66 Gy) were reported. Conclusion: Our approach results in a response rate of 40% or more, with acceptable toxicity. 18 F-FMISO uptake in NSCLC patients is strongly associated with poor prognosis features that could not be reversed by radiotherapy doses up to 86 Gy., (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results